UNSPSC 51313437: Pheniramine hydrogen maleate

This classification denotes a histamine-1 receptor antagonist with the molecular formula C16H20N2.C4H4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier NYW905655B, chemically known as n,n-dimethyl-3-phenyl-3-(2-pyridyl)propylamine hydrogen maleate, but more generally known as pheniramine hydrogen maleate, which bears US NIH Compound Identifier 6433160. European Medicines Agency schedules pheniramine hydrogen maleate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09768MIG.

Most nations, for tariff purposes, schedule pheniramine hydrogen maleate under HS 29333999. SMILES: CN(C)CCC(C1CCCCC1)C2CCCCN2.C(=C\C(=O)O)\C(=O)O.

UNSPSC 51313437 Pheniramine hydrogen maleate is a Commodity code, yet the recent state and local solicitations tagged under it do not involve this antihistamine compound at all. The three most recent opportunities are for naloxone and drug deactivation systems (Seminole County, Florida), direct-to-manufacturer pharmacy prescription programs (Texas Health and Human Services Commission), and generic multi-source pharmaceuticals and over-the-counter products through a cooperative purchasing vehicle (Minnesota Multistate Cooperative Purchasing Alliance). The code shows little relevant recent activity, and the posted opportunities represent a significant mismatch between the code's nominal scope and what is actually being procured.

The geographic spread of the three opportunities spans Florida, Texas, and Minnesota, reflecting activity across distinct issuing-body types: a county health department, a state health agency, and a cooperative purchasing organization administered by a state department of administration. No repeat buyers or concentrated procurement activity appears under this code in the recent record. The Seminole County naloxone procurement (IFB 60459723LAS, due July 26, 2023) sought 1,900 units annually through a competitive bidding process with quarterly deliveries. The Texas Health and Human Services Commission issued an RFI (HHS0017013) posted April 3, 2026 to gather vendor capabilities on direct-to-manufacturer prescription programs, while the Minnesota Multistate Cooperative Purchasing Alliance released an RFP (S1070000015802, due March 26, 2026) for generic pharmaceuticals and OTC products across multiple participating jurisdictions. Given the consistent mismatch between the code designation and the actual work being solicited, this code warrants review in your taxonomy classification process before committing resources to pursuit.